5 Azacytidine

DRUG3 trials

Sponsors

King's College London, The Hospital for Sick Children, Mohammed Milhem

Conditions

Childhood Solid TumorEpendymoma, Recurrent ChildhoodLeukemia, Myeloid, AcuteLocally Advanced Solid TumorMetastatic TumorMyelodysplastic SyndromesRecurrent Childhood CNS TumorSolid Tumor

Phase 1

COZMOS:Phase I/Ib Trial of Combined 5'Azacitidine and Carboplatin for Recurrent/Refractory Pediatric Brain/Solid Tumors

CompletedNCT03206021

The Hospital for Sick ChildrenChildhood Solid Tumor, Ependymoma, Recurrent Childhood, Recurrent Childhood CNS Tumor

Start: 2017-08-01End: 2024-03-01Updated: 2024-04-05

5-Azacitidine Plus PD-1/PD-L1 Inhibitor With PD-1/PD-L1 Refractory Tumors

RecruitingNCT07404332

Mohammed MilhemLocally Advanced Solid Tumor, Metastatic Tumor, Solid Tumor

Start: 2026-02-11End: 2031-02-28Target: 35Updated: 2026-05-28

Phase 2

Azacytidine for the Treatment of Myelodysplastic Syndromes/Acute Myeloid Leukemia (MDS/AML) With High Risk (Chromosome 7 and or Complex) Cytogenetic Abnormalities

CompletedNCT00915785

King's College LondonLeukemia, Myeloid, Acute, Myelodysplastic Syndromes

Start: 2005-11-30Updated: 2013-04-24

Related Papers

Histone H3-wild type diffuse midline gliomas with H3K27me3 loss are a distinct entity with exclusive EGFR or ACVR1 mutation and differential methylation of homeobox genes

Scientific Reports2023-03-0717 citations